Characterization of DCTN1 genetic variability in neurodegeneration

C. Vilariño-Güell, C. Wider, A. I. Soto-Ortolaza, S. A. Cobb, J. M. Kachergus, B. H. Keeling, J. C. Dachsel, M. M. Hulihan, D. W. Dickson, Z. K. Wszolek, R. J. Uitti, N. R. Graff-Radford, B. F. Boeve, K. A. Josephs, B. Miller, K. B. Boylan, K. Gwinn, C. H. Adler, J. O. Aasly, F. HentatiA. Destée, A. Krygowska-Wajs, M. C. Chartier-Harlin, O. A. Ross, R. Rademakers, M. J. Farrer

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


OBJECTIVE:: Recently, mutations in DCTN1 were found to cause Perry syndrome, a parkinsonian disorder with TDP-43-positive pathology. Previously, mutations in DCTN1 were identified in a family with lower motor neuron disease, in amyotrophic lateral sclerosis (ALS), and in a family with ALS/frontotemporal dementia (FTD), suggesting a central role for DCTN1 in neurodegeneration. METHODS:: In this study we sequenced all DCTN1 exons and exon-intron boundaries in 286 samples diagnosed with Parkinson disease (PD), frontotemporal lobar degeneration (FTLD), or ALS. RESULTS:: This analysis revealed 36 novel variants (9 missense, 5 silent, and 22 noncoding). Segregation analysis in families and association studies in PD, FTLD, and ALS case-control series did not identify any variants segregating with disease or associated with increased disease risk. CONCLUSIONS:: This study suggests that pathogenic mutations in DCTN1 are rare and do not play a common role in the development of Parkinson disease, frontotemporal lobar degeneration, or amyotrophic lateral sclerosis.

Original languageEnglish (US)
Pages (from-to)2024-2028
Number of pages5
Issue number23
StatePublished - Jun 9 2009

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Characterization of DCTN1 genetic variability in neurodegeneration'. Together they form a unique fingerprint.

Cite this